Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan

[1]  H. Kelly,et al.  Withdrawal from Lorazepam in Critically III Children , 2006, The Annals of pharmacotherapy.

[2]  R. Egeler,et al.  Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity , 2005, Bone Marrow Transplantation.

[3]  M. Björkholm,et al.  Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics , 2004, Cancer Chemotherapy and Pharmacology.

[4]  H. Tran,et al.  Lorazepam for seizure prophylaxis during high-dose busulfan administration , 2002, Bone Marrow Transplantation.

[5]  T. Madden,et al.  Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies , 2000, Bone Marrow Transplantation.

[6]  B L Ehrenberg,et al.  Kinetics and dynamics of lorazepam during and after continuous intravenous infusion , 2000, Critical care medicine.

[7]  B. Uthman,et al.  A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. , 1998, The New England journal of medicine.

[8]  G. Vassal,et al.  Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. , 1990, Cancer research.

[9]  T. Shea,et al.  Measurement of busulfan in plasma by high-performance liquid chromatography. , 1987, Journal of chromatography.